Answers are grounded in this paper and cite their sources.
Background Head and neck cancers (HNC) comprise 5% of all malignancies worldwide. Cetuximab is the first targeted therapy to demonstrate a significant survival benefit in patients with locally advanced HNC (LAHNC) and recurrent or metastatic HNC (R/MHNC). In view of this, we undertook this economic evaluation to ascertain the costs and health benefits associated with (i) the use of RT + CTX over RT alone for LAHNC patients who are ineligible for cisplatin-based chemoradiotherapy and (ii) CT + CTX over CT alone for R/MHNC patients from the perspective of Indian healthcare system. Methods A Markov model was constructed to assess the lifetime costs and health outcomes using cetuximab in combination with radiotherapy (RT + CTX) for treatment of cisplatin-ineligible LAHNC ( Analysis I ), and cetuximab in combination with platinum-based chemotherapy (CT + CTX) for treatment of R/MHNC patients in India ( Analysis II ). Using an abridged societal perspective lifetime costs and quality adjusted life years (QALYs) were evaluated, discounting future costs and consequences at 3% annually. For both the analyses, costs of original as well as biosimilar cetuximab were evaluated. The cost-effectiveness was assessed in terms of incremental cost effectiveness ratio (ICER) which was compared against a threshold of 1-time per capita gross domestic product (GDP) for India in 2024–25 (₹ 247,045; US$ 2,697). Results Adding biosimilar cetuximab to radiotherapy for cisplatin-ineligible LAHNC patients resulted in 2.73 (95% CI: 2.11–3.30) QALYs, while adding biosimilar cetuximab to platinum-based chemotherapy for R/MHNC resulted in 0.78 (95% CI: 0.61–0.96) QALYs over the modelled lifetime horizon. The incremental cost per QALY gained was found to be ₹ 501,320 with use of RT + CTX and ₹ 15,023,037 with use of CT + CTX. At the currently recommended willingness to pay (WTP) threshold, treatment with cetuximab is not a cost-effective treatment option for patients with LAHNC and R/MHNC patients respectively in India. A 50% reduction in the price of biosimilar would make it a cost-effective option for treatment of LAHNC in India. Conclusion Strategic purchasing of biosimilar cetuximab at reduced price can provide good value for money for treatment of patients with LAHNC.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: